ScreenerHero

UPB Upstream Bio, Inc.

NAS · US · Healthcare · Biotechnology · upstreambio.com
4.610USD+0.44%Mkt Cap: 252.49M $P/E: —

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of sev…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap252.49M USD
Enterprise Value-8.95M USD
Revenue (TTM)3.16M USD
Gross Profit3.16M USD
Net Income (TTM)-143.44M USD
Revenue/Share0.06 USD
Last Price4.610 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees75
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.64
PEG—
EV/EBITDA0.05
EV/Revenue-2.84
P/S79.61
P/B0.93
EPS (TTM)-2.88
EPS (Forward)-2.80
52W Range
4.5000% of range33.68
52W High33.68 USD
52W Low4.500 USD
Profitability
Gross Margin100.00%
Oper. Margin-5480.98%
EBITDA Margin0.00%
Profit Margin-5026.03%
ROE-42.22%
ROA-40.55%
Growth
Revenue Growth-17.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-133.28M USD
CapEx (TTM)165.00K USD
FCF Margin-2742.75%
FCF Yield-34.30%
Net Debt-260.35M USD
Net Debt/EBITDA1.53
Balance Sheet
Debt/Equity0.00
Current Ratio27.99
Quick Ratio26.38
Book Value/Sh4.95 USD
Cash/Share4.77 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)31.14 USD
Upside (mean)+575.6%
Target Range9.000 USD – 75.00 USD
9.000+575.6% to mean75.00
# Analysts7
Ownership
Shares Out.54.77M
Float42.81M
Insiders14.78%
Institutions92.44%
Short Interest
Short Ratio7.4d
Short % Float12.60%
Short % Out.8.20%
Shares Short4.49M
Short (prev mo.)4.02M
Technical
SMA 506.224 (-25.9%)
SMA 20011.71 (-60.6%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)668.13K
Avg Vol (10d)695.95K
Technical Indicators
RSI (14)26.5
MACD-0.4042
MACD Signal-0.3767
MACD Hist.-0.0275
BB Upper5.919 USD
BB Middle5.261 USD
BB Lower4.603 USD
BB Width25.01%
ATR (14)0.3297 USD
Vol Ratio (20d)1.38x